Cystic fibrosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{SHH}} | {{CMG}}; {{AE}} {{SHH}} | ||
{{Cystic fibrosis}} | {{Cystic fibrosis}} | ||
Line 7: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
* Inhaled osmotic agent/ Hypertonic saline: Increase the airway fluid layer | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] |
Revision as of 20:44, 13 February 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Cystic fibrosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cystic fibrosis medical therapy On the Web |
American Roentgen Ray Society Images of Cystic fibrosis medical therapy |
Risk calculators and risk factors for Cystic fibrosis medical therapy |
Overview
Medical Therapy
- Inhaled osmotic agent/ Hypertonic saline: Increase the airway fluid layer